03/06/25 (Agence Europe) – The European Commission, with the support of the European Investment Bank (EIB), will provide €20 million in the development of nasal sprays designed to protect against respiratory viruses., the institution announced on Tuesday 3 June. The Commission, through the Health Emergency Preparedness and Response Authority (HERA), has signed an investment agreement with the Dutch biotechnology company Leyden Labs. The nasal spray delivers antibodies directly into the nasal cavity, stopping infections at the point of entry, and potentially preventing onward transmission. By targeting commonalities among virus families, rather than one variant in particular, this innovative approach provides broad protection against various existing and new viruses. (LC)